Skip to main content
. 2015 Nov 12;2015:838652. doi: 10.1155/2015/838652

Figure 3.

Figure 3

Effects of the PPARγ inhibitor GW9662 on HB4a and Hb4aC5.2 cells. (a) Relative expression of FAT/CD36, FABP4, DGAT, SREBP1, LIPIN1, and FASN in HB4a and HB4aC5.2 cells treated with GW9662 (1 μL/mL) for 72 h. DMSO was used as a control (CNT). Data were obtained from an experiment performed in quadruplicate. The real-time PCR reaction was performed in duplicate. ∗ P < 0.001 versus CNT. Proliferation rates for untreated (b) and treated (c) HB4a and HB4aC5.2 cells. Untreated cells were cultured in standard medium without additional stimulation for 5 d. Treated cells were incubated with medium containing GW9662 (GW) or DMSO as a control (CNT) for 0, 12, 24, 48, and 72 h. (b) ∗ P < 0.001 versus HB4a. ∗∗ P < 0.001 versus HB4a CNT. (c) ∗ P < 0.001 versus HB4aC5.2 CNT. ∗∗ P < 0.001 versus HB4aC5.2 GW.